Eleni Tiniakou is a Rheumatology/Immunology physician. OpenAlex indexes 87 publications with 2,868 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St Ste 450
Houston, TX 770303008
Telephone
713-500-6900Provider last certified this registry record 2 May 2025.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20251 payment
- Octapharma USA, Inc.Program year20251 payment
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
42.5%Salt solutions42.5%Sodium Chloride100%Part D<11 patientsRespiratory
23.9%Histamine-1 Receptor Antagonist13.3%Diphenhydramine Hcl100%Part D<11 patientsPhenothiazine10.6%Promethazine Hcl100%Part D<11 patientsCancer & immunology
23%Folate Analog Metabolic Inhibitor12.4%Methotrexate100%Part D<11 patientsJAK inhibitor10.6%Xeljanz100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- RNA: Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in scleroderma
University of Texas Hlth Sci Ctr Houston
FY2025$158,729K08AR077732
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”